The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes
NCT07348432 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 106
Last updated 2026-01-16
Summary
Type 1 diabetes is an autoimmune health condition that requires daily injections of insulin. Insulin allows the body to use energy from carbohydrates in food. Disordered eating behaviours, like restricting food intake to lose body weight, are more common in women and people with type 1 diabetes, compared to those without because they must practice carbohydrate counting. Carbohydrate counting means identifying, measuring, and planning carbohydrate intake to match insulin dosage. New technologies, such as automated insulin delivery (AID) systems adjust insulin delivery in a blood sugar responsive manner. AID is rapidly replacing conventional insulin delivery like injections or non-automated insulin pumps since it reduces management burden and improves blood sugar levels. It is not known if AID reduces food management and disordered eating behaviours. This study aims to: 1. investigate the relationship between AID and eating behaviours according to gender for youth (12 to 17 years), and adults (18 years and older). 2. Determine the limit of carbohydrate counting inaccuracy to maintain stable blood sugar levels according to insulin delivery method (AID, injections, or pumps). It is hypothesized that those who use AID will have lower disordered eating behaviours and will maintain stable blood sugar levels while allowing for higher carbohydrate counting inaccuracy. This will be a cross-sectional cohort study of people with type 1 diabetes who are 12 years of age or over. Participants will be recruited through the BETTER registry and social medias across Canada. This research is needed to improve nutrition guidelines for type 1 diabetes in the context of new technologies like AID. Evidence from this study may reduce food management burden, lower the risk of disordered eating behaviours, and prevent eating disorders and medical complications.
Conditions
- Insulin Dependent Diabetes Mellitus
- Feeding and Eating Disorders
- Eating Behavior
- Type 1 Diabetes
- Autoimmune Diseases
- Endocrine System Diseases
Interventions
- DEVICE
-
Automated Insulin Delivery (AID) Systems
AID automatically adjusts insulin delivery by using continuously measured blood glucose levels. AID use will be determined through the initial questionnaire through the following questions: Do you currently use the pump as an automated insulin delivery system (connected to a CGM with automated insulin adjustments)? Yes, a commercial AID with control IQ (Tandem) or SmartGuard (Medtronic) Yes, a non-commercial open-source do-it yourself AID (e.g., Loop) No, they use it as a manual (non-automated) pump or with a suspend on low functionality (e.g., Basal IQ) I prefer not to answer I don't know The type of AID system (hybrid, advanced hybrid, etc.) will also be confirmed. The exposure variable will be coded as a binary-categorical variable of AID use (yes or no) with no representing all other non-AID insulin pumps or injections.
- BEHAVIORAL
-
Carbohydrate Counting Inaccuracy Percentage
Carbohydrate counting inaccuracy: will be determined by subtracting the estimated carbohydrates (by participant) by the actual amount of carbohydrate (through diet analysis) divided by the actual amount of carbohydrate, multiplied by 100, to determined the percentage. Estimated carbohydrate counts will be entered at each meal and snack by the participant in a daily log provided to the participant. Carbohydrate amounts will be collected through a 4-day food diary through the phone application Keenoa (carb count from the app will be blinded to the participant), and reviewed by a research assistant with education in dietetics.
Sponsors & Collaborators
-
Laval University
collaborator OTHER -
Université de Montréal
collaborator OTHER -
University of Windsor
collaborator OTHER - lead OTHER
Principal Investigators
-
Anne-Sophie Brazeau, PhD · McGill University
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-07-29
- Primary Completion
- 2026-01-31
- Completion
- 2026-05-01
Countries
- Canada
Study Locations
More Related Trials
-
Liraglutide in Type 1 Diabetes
NCT01612468 ·Status: COMPLETED ·Phase: PHASE4
-
Meal Frequency and Glycemic Control in Individuals With Type 1 Diabetes
NCT06934707 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Individualised Postprandial Glucose Responses in Type 1 Diabetes
NCT05231642 ·Status: COMPLETED ·Phase: NA
-
Alternative Delivery of Dose Adjustment For Normal Eating (DAFNE) Trial in Patients With Type 1 Diabetes
NCT01069393 ·Status: COMPLETED ·Phase: NA
-
Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes
NCT06105931 ·Status: RECRUITING ·Phase: PHASE1
-
Liraglutide as add-on to Insulin in Type 1 Diabetes
NCT02092896 ·Status: COMPLETED ·Phase: PHASE3
-
Intermittent Fasting in Adults With Type 1 Diabetes
NCT06134986 ·Status: COMPLETED ·Phase: NA
-
Glucose Variability in Subclinical Hypertrophy
NCT02748434 ·Status: TERMINATED ·Phase: NA
-
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
NCT01843881 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Prevalence of Overweight and Obesity in Adult Patients Suffering From Type 1 Diabetes
NCT05713448 ·Status: RECRUITING
-
Liraglutide in Newly Onset Type 1 Diabetes.
NCT01879917 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Eating Disorders in Type 1 Insulin-dependent Diabetes Patients
NCT04506216 ·Status: COMPLETED ·Phase: NA
-
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
NCT03444142 ·Status: UNKNOWN ·Phase: PHASE4
-
Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes
NCT01747967 ·Status: COMPLETED ·Phase: NA
-
Study TO Prevent Diabetes With Short-term Insulin Glargine Only
NCT01276912 ·Status: UNKNOWN ·Phase: NA
-
Liraglutide in Adolescents With Type 1 Diabetes
NCT02516657 ·Status: COMPLETED ·Phase: PHASE3
-
Development of Predictive Biomarkers
NCT03423862 ·Status: COMPLETED
-
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
NCT01843855 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP-1 Therapy
NCT07313384 ·Status: RECRUITING
-
Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study
NCT07001553 ·Status: COMPLETED
-
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
NCT00747968 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics
NCT02042664 ·Status: COMPLETED ·Phase: PHASE3
-
Optimising Health in Type 1 Diabetes
NCT02903615 ·Status: COMPLETED ·Phase: NA
-
Early Insulin Treatment in Patients With Latent Autoimmune Diabetes
NCT01109927 ·Status: COMPLETED ·Phase: PHASE4
-
GLP-1 REceptor Agonists and Real World EvIdeNce
NCT03959865 ·Status: UNKNOWN